New radioactive bullet targets Hard-to-Treat prostate cancer
NCT ID NCT04644770
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals are to find a safe dose and check for side effects, with some early signs of effectiveness also being measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-69086420 (a drug that delivers a radioactive particle to prostate cancer cells)
What this could lead to
If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial, so the main goal is safety, not effectiveness. The drug may cause serious side effects or not shrink tumors. It is also only for a specific type of advanced prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
City of Hope
Duarte, California, 91010, United States
-
East Jefferson General Hospital
Metairie, Louisiana, 70006, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Tulane University Hospital & Clinics
New Orleans, Louisiana, 70112, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
XCancer Omaha / Urology Cancer Center
Omaha, Nebraska, 68130, United States